Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...

The pharmaceutical giant’s key U.S. intellectual property on the active ingredient in Januvia was set to expire in early 2023 ...